PATENT CLAIM ANALYSIS

Application Number: 15899539
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["514", "646000"]

Abstract:
Aerosolized dapsone (or alternatively, an aqueous formulation of dapsone) is used to treat airway inflammation, particularly chronic neutrophil-dominated inflammation. Diseases that may be prevented or treated by the methods include chronic obstructive pulmonary diseases (COPDs), asthma, cystic fibrosis, and others.

Claim (Index 4):
The method of  claim 1 , wherein said patient is suffering from a disease or condition selected from the group consisting of cystic fibrosis, bronchiectasis, bronchiolitis obliterans, emphysema, chronic bronchitis, chronic rhinosinusitis, toxic inhalation injury, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, asthma, and chronic airway inflammation.

Metadata:
- Claim Count in Document: 3.0
- Percentile: 88.0
- Lexical Diversity: 1.275
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14970028', '14191219', '12574666', '14699620', '12972908']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7871453478257031
- 35 USC 102 Novelty (BERT): 0.4816242377349968
- Combined Prediction Score: 0.7565932368166325
- Mean Citation Score: 240.96068
- Max Citation Score: 243.88939
- Similarity Product: 226.2064811867213

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test